Weritasu In Shiriko
130A.TTSE GROWTHPharmaceutical
Filed as Veritas In Silico Inc. (2024-03–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Operating income | −¥397m | −¥213m | ¥38m | −¥139m | — | — |
| Ordinary income | −¥391m | −¥234m | ¥36m | −¥138m | −¥240m | −¥297m |
| Total assets | ¥1.9bn | ¥2.2bn | ¥1.7bn | ¥1.6bn | ¥1.8bn | ¥596m |
| Net assets / equity | ¥1.8bn | ¥2.2bn | ¥1.6bn | ¥1.5bn | ¥1.7bn | ¥516m |
| Operating cash flow | −¥299m | −¥218m | ¥69m | −¥149m | −¥235m | — |
| EPS (basic) | ¥-65.62 | ¥-37.11 | ¥6.01 | ¥-25.7 | ¥-51.92 | ¥-270.82 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 56 figures · EDINET |